NCT04359914 (NCoV) is a clinical trial in Critical Illness, sponsored by University of Rostock.

Who is sponsoring NCT04359914?

NCT04359914 is sponsored by University of Rostock.

What condition does NCT04359914 study?

NCT04359914 studies Critical Illness, COVID-19, Central Nervous System Injury, Delirium, Encephalopathy.

Is NCT04359914 still recruiting?

NCT04359914 is currently completed. Last updated 29 January 2024.

Last reviewed 2024-01-29 · How we verify

NCT04359914: NCoV

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neurocognitive Impairment in Patients With COVID-19

Completed Last updated 29 January 2024

What this trial tests

trial in Critical Illness in 118 participants. Completed in 31 December 2023.

Timeline

15 April 2020

Primary endpoint
31 March 2021

31 December 2023

Quick facts

Lead sponsor	University of Rostock
Status	Completed
Study type	OBSERVATIONAL
Enrollment	118
Start date	15 April 2020
Primary completion	31 March 2021
Estimated completion	31 December 2023
Sites	1 location across Germany

Conditions studied

Critical Illness — all drugs for Critical Illness →
COVID-19 — all drugs for COVID-19 →
Central Nervous System Injury — all drugs for Central Nervous System Injury →
Delirium — all drugs for Delirium →

Sponsor

University of Rostock

Who can join

Eligibility, any sex, with Critical Illness or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Delirium and acute neurocognitive impairment are increasingly observed in adult and pediatric patients with COVID-19. Prospective clinical studies combining clinical and laboratory examinations including specific biomarkers of neuroaxonal injury were not performed for COVID-19. The value of biomarkers of neuroaxonal injury was proven in preliminary studies. These biomarkers could thus contribute to the systematic detection of neurocognitive impairment in patients with COVID-19. Due to worldwide increasing numbers of hospitalized patients with COVID-19, biomarkers of neuroaxonal injury are highly valuable to detect and monitor cognitive impairment, especially with regard to limited resources available to perform time-consuming brain imaging. Biomarkers of neuroaxonal injury are therefore not only of great interest to detect neurocognitive impairment but also to quantify the severity of brain injury in patients with COVID-19.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Neuropsychiatric Disorders and COVID-19: What We Know So Far.
Majolo F, Silva GLD, Vieira L, Anli C, et al · · 2021 · cited 12× · PMID 34577633 · DOI 10.3390/ph14090933
Worldwide epidemiology of neuro-coronavirus disease in children: lessons for the next pandemic.
Alcamo AM, McGuire JL, Kanthimathinathan HK, Roa JD, et al · · 2021 · cited 6× · PMID 34654049 · DOI 10.1097/mop.0000000000001069
SARS-Cov-2 Damage on the Nervous System and Mental Health.
Boulkrane MS, Ilina V, Melchakov R, Arisov M, et al · · 2022 · cited 4× · PMID 34191699 · DOI 10.2174/1570159x19666210629151303
Impending cognitive and functional decline in COVID-19 survivors. Comment on Br J Anaesth 2021; 126: 44-7.
Magoon R. · · 2021 · cited 4× · PMID 33390260 · DOI 10.1016/j.bja.2020.12.009
No substantial neurocognitive impact of COVID-19 across ages and disease severity: a multicenter biomarker study of SARS-CoV-2 positive and negative adult and pediatric patients with acute respiratory tract infections.
Ehler J, Klawitter F, von Möllendorff F, Zacharias M, et al · · 2025 · cited 2× · PMID 39352661 · DOI 10.1007/s15010-024-02406-7

Verify or expand the search:

Other recruiting trials for Critical Illness

Currently open trials in the same condition.

NCT06189924 — Exhaled Breath Condensate Analysis in Mechanically Ventilated Patients · recruiting
NCT07418242 — Prognostic Value of Novel Biomarkers on Adverse Renal Outcomes in High-Risk Cardiac Surgery Patients · recruiting
NCT07101640 — PK, Safety and Preliminary Efficacy Study of Montelukast in Critically Ill Infants With Developing Bronchopulmonary Dysp · Phase 1, PHASE2 · recruiting
NCT07177183 — Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure · NA · recruiting
NCT07369258 — Clinical Application of Listening to Music to Prevent Delirium in the Intensive Care Unit · NA · recruiting

Other University of Rostock trials

Trials by the same sponsor.

NCT06489470 — Strokectomy in Malignant Cerebral Media Infarction · NA · recruiting
NCT06175429 — Prognostic Value of Exhaled Isoprene Levels for Morbidity and Functional Outcome in Cardiosurgical Patients · unknown
NCT04972617 — Characterization of the Efficacy of Furosemide Depending on Albumin Function · completed
NCT06318208 — Pulmonary Function in Non-hospitalized Adults and Children After Mild COVID-19 · completed
NCT05885620 — SAMi Intervention Study to Evaluate Smartwatch Interventions in Persons With MCI and Dementia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04359914 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rostock
Last refreshed: 29 January 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04359914.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing